Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
US10712349B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 14, 2015 |
| Grant date | Jul 14, 2020 |
| Priority date | — |
| Expiry date | Apr 14, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/347
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention is directed to KIM-1 polypeptide as a plasma acute and chronic kidney injury and renal cell carcinoma biomarker, and methods and kits comprising the use of agents specific to KIM-1 for facilitating and enhancing the diagnosis of kidney injury or carcinoma. The present invention is based on the discovery that measuring KIM-1 levels in the blood is more accurate and reliable than measuring KIM-1 levels in the urine for the diagnosis of subjects with proximal kidney tubule injury or kidney cancer. The invention is directed to methods for diagnosis of acute kidney injury, chronic kidney disease (CKD), and renal cell cancer by determining and monitoring the levels of KIM-1 polypeptide in a blood sample, such as plasma or serum sample.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.